EODData

MEMBERSHIP REGISTER LOG IN

FRA, E08A: Exagen Inc

25 Mar 2026
LAST:

2.340

CHANGE:
 0.08		OPEN:
2.340		HIGH:
2.340		ASK:
0.000		VOLUME:
18
CHG(%):
3.31		PREV:
2.420		LOW:
2.340		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
25 Mar 262.3402.3402.3402.34018
24 Mar 262.4202.4202.4202.42018
23 Mar 262.3402.3402.3402.34018
20 Mar 262.5202.5202.5202.52018
19 Mar 262.5802.5802.5802.5800
18 Mar 262.7202.7202.7202.7200
17 Mar 262.6802.6802.6802.6800
16 Mar 262.6602.6602.6602.6600
13 Mar 262.7002.7002.7002.7000
12 Mar 262.6202.6202.6202.62018

PROFILE

Name:Exagen Inc
About:Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Sector:Healthcare
Address:1261 Liberty Way, Vista, CA, United States, 92081
Website:https://www.exagen.com
ISIN:US30068X1037
LEI:549300JV2CYDOME5OO17

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-6.63 
Forward P/E:-3.04 
PEG Ratio:-3.04 
Price to Sales:1.96 
Price to Book:8.05 
Profit Margin:-0.30 
Operating Margin:-0.18 
Return on Assets:-0.15 
Return on Equity:-1.23 
Revenue:53.97M 
Shares:22.0M 
Market Cap:51.49M 

TECHNICAL INDICATORS

MA5:2.444.3%
MA10:2.569.3%
MA20:2.7517.7%
MA50:3.1333.7%
MA100:5.00113.5%
MA200:6.28168.2%
RSI14:23.88 
WPR14:-100.00 
MTM14:-0.58
ROC14:-0.20 
ATR:0.11 
Week High:2.7216.2%
Week Low:2.340.0%
Month High:3.1635.0%
Month Low:2.34168.2%
Year High:10.20335.9%
Year Low:2.340.0%
Volatility:45.56